• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    2/3/23 12:31:15 PM ET
    $ALR
    $BGXX
    $CLLS
    $GENE
    Hospital/Nursing Management
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ALR alert in real time by email

    Gainers

    • Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 163.5% to $16.6 during Friday's regular session. As of 12:30 EST, Reshape Lifesciences's stock is trading at a volume of 8.2 million, which is 3041.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.6 million.
    • Genetic Technologies (NASDAQ:GENE) stock increased by 73.76% to $1.75. Trading volume for this security as of 12:30 EST is 78.1 million, which is 39719.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.0 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares rose 62.05% to $2.3. As of 12:30 EST, this security is trading at a volume of 30.2 million shares, making up 2201.1% of its average full-day volume over the last 100 days. The company's market cap stands at $19.2 million.
    • AlerisLife (NASDAQ:ALR) shares increased by 58.06% to $1.28. As of 12:30 EST, this security is trading at a volume of 3.2 million shares, making up 3152.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $41.7 million.
    • Magenta Therapeutics (NASDAQ:MGTA) shares increased by 40.54% to $0.79. Magenta Therapeutics's stock is trading at a volume of 23.2 million shares as of 12:30 EST. This is 1222.3% of its average full-day volume over the last 100 days. The company's market cap stands at $48.0 million.
    • Bright Green (NASDAQ:BGXX) stock rose 37.26% to $1.46. As of 12:30 EST, this security is trading at a volume of 29.2 million shares, making up 1015.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $246.3 million.

    Losers

    • MDxHealth (NASDAQ:MDXH) stock fell 36.8% to $3.8 during Friday's regular session. Trading volume for MDxHealth's stock is 1.4 million as of 12:30 EST. This is 58963.2% of its average full-day volume over the last 100 days. The company's market cap stands at $61.8 million.
    • Cellectis (NASDAQ:CLLS) stock fell 24.24% to $2.47. Trading volume for this security as of 12:30 EST is 1.2 million, which is 1092.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $112.5 million.
    • Summit Therapeutics (NASDAQ:SMMT) stock fell 22.94% to $2.99. Trading volume for this security as of 12:30 EST is 5.3 million, which is 55.7% of its average full-day volume over the last 100 days. The company's market cap stands at $631.8 million.
    • Tenax Therapeutics (NASDAQ:TENX) stock decreased by 20.37% to $1.76. Trading volume for this security as of 12:30 EST is 6.4 million, which is 761.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.0 million.
    • Vyant Bio (NASDAQ:VYNT) shares decreased by 18.9% to $0.84. As of 12:30 EST, Vyant Bio's stock is trading at a volume of 448.5K, which is 111.7% of its average full-day volume over the last 100 days. The company's market cap stands at $4.9 million.
    • Twist Bioscience (NASDAQ:TWST) shares declined by 16.54% to $25.79. Trading volume for Twist Bioscience's stock is 1.5 million as of 12:30 EST. This is 119.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.4 billion. As per the news, the Q1 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALR
    $BGXX
    $CLLS
    $GENE

    CompanyDatePrice TargetRatingAnalyst
    Cellectis S.A.
    $CLLS
    2/17/2026$7.00Buy
    Jefferies
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Twist Bioscience Corporation
    $TWST
    11/4/2025$41.00Overweight
    Stephens
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    More analyst ratings

    $ALR
    $BGXX
    $CLLS
    $GENE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Werner Robert F. sold $79,080 worth of shares (1,693 units at $46.71), decreasing direct ownership by 3% to 55,045 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/25/26 4:05:19 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Laponis Adam sold $97,390 worth of shares (2,085 units at $46.71), decreasing direct ownership by 2% to 128,291 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/25/26 4:05:17 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and COO Finn Patrick John sold $200,572 worth of shares (4,294 units at $46.71), decreasing direct ownership by 1% to 284,129 units (SEC Form 4)

    4 - Twist Bioscience Corp (0001581280) (Issuer)

    2/25/26 4:05:21 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    SEC Filings

    View All

    Amendment: SEC Form 10-Q/A filed by Twist Bioscience Corporation

    10-Q/A - Twist Bioscience Corp (0001581280) (Filer)

    2/26/26 4:19:15 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by MDxHealth SA

    6-K - MDxHealth SA (0001872529) (Filer)

    2/26/26 4:07:50 PM ET
    $MDXH
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Summit Therapeutics Inc.

    S-8 - Summit Therapeutics Inc. (0001599298) (Filer)

    2/23/26 4:58:58 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ALR
    $BGXX
    $CLLS
    $GENE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 26, 2021 - Coronavirus (COVID-19) Update: March 26, 2021

    For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato

    3/26/21 3:51:09 PM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

    CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL. Details of presentation:Format: Fireside chatParticipants: Chris Giordano, President & Chief Executive Officer; Stuart Rich, M.D., Chief Medical Officer; Douglas Randall, Chief Business OfficerDate and Time: March 10, 2026, at 2:20 p.m. ET The

    3/3/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics to Present at Upcoming Investor Conferences

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences: TD Cowen's 46th Annual Health Care Conference in Boston on Monday, March 2, 2026 Fireside chat 2:30pm ET Jefferies Conference in Miami on Tuesday, March 10, 2026 Investor meetings only Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026 Fireside chat 2:15pm ET The fireside chats will be available live on our website: www.

    2/26/26 6:45:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

    Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consiste

    2/26/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Cellectis with a new price target

    Jefferies resumed coverage of Cellectis with a rating of Buy and set a new price target of $7.00

    2/17/26 7:48:16 AM ET
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Summit Therapeutics

    Wolfe Research initiated coverage of Summit Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MDxHealth SA

    SC 13G - MDxHealth SA (0001872529) (Subject)

    11/14/24 3:15:43 PM ET
    $MDXH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

    SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 12:21:05 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    Financials

    Live finance-specific insights

    View All

    Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

    Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consiste

    2/26/26 4:00:00 PM ET
    $MDXH
    Medical Specialities
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

    HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase III ILLUMINE Study in 1L PD-L1 Positive R/M HNSCC Sponsored by Cooperative Group, GORTEC, to Initiate; First Patient Expected in Early Q2 2026 US FDA Accepts BLA Filing Based on HARMONi Study; PDUFA Goal Action Date of November 14, 2026 First Patient Dosed in Revolution Medicines Clinical Trial Collaboration Evaluating Ivonescimab in Combination with RAS(ON) Inhibitors in RAS Mutant Tumors GSK Collaboration Clinical Trials Evaluating Ivonescimab in

    2/23/26 4:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

    Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, phy

    2/17/26 5:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALR
    $BGXX
    $CLLS
    $GENE
    Leadership Updates

    Live Leadership Updates

    View All

    Vyome Announces New Board of Directors with Deep MIT and AI Ties

    Heavily shareholder-aligned board and management team completely replaces ReShape team as Vyome prepares for public listing on August 15, 2025 Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ:RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Holdings, Inc. post-closing and trade under the ticker symbol HIND. The new Vyome board members, which include four Massachusetts Institute of Technology (MIT) alums, are all persons with prior

    8/12/25 9:48:00 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care

    Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

    Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios

    8/6/25 8:00:00 AM ET
    $TWST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ANDMORE Establishes New Executive Team to Support Growth Plan

    Robert Klein Appointed Chief Financial Officer; Brings Extensive Financial and Real Estate Expertise Entirely New Executive Team Installed Under Jon Pertchik Leadership Leadership Changes Will Support Growth Plan to Improve Operations for the Category Leader ANDMORE®, the largest owner and operator of tradeshows in the U.S., today announced the appointment of Robert Klein as Chief Financial Officer. Klein joins ANDMORE from Postal Realty Trust, Inc. (NYSE:PSTL), where he served as Chief Financial Officer since 2021. "Nothing transforms a company more than excellent senior leadership, with diverse skillsets and broad-based experience," said Jonathan Pertchik, CEO of ANDMORE. "Our lea

    8/6/25 7:30:00 AM ET
    $PSTL
    $RMR
    $ALR
    Real Estate Investment Trusts
    Real Estate
    Professional Services
    Consumer Discretionary